Pioneering the development of next-generation oral immunotherapies
- CHAIN is developing novel oral immunotherapies against epithelial cancers using its proprietary bacterial-based technology (CADD).
- Introduction and application of CADD: engineering non-pathogenic Clostridium butyricum for precise, oral delivery of antigens, directly targeting mucosal linings for a safe and durable response
- Validation and refinement of the CADD technology to date; plans and challenges associated with developing LBPs